{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":18,"total_is_capped":false,"direct_labels_cover":0,"predictions_cover":18,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12","author_layer_release":"2026-06-26"},"query_hash":"f45526ca5810","filters":{"venue":"ESMO rare cancers."}},"results":[{"id":"W4417530834","doi":"10.1016/j.esmorc.2025.100073","title":"RADIOLOGIC RESPONSES IN EPITHELIOID HEMANGIOENDOTHELIOMA: BEYOND RECIST?","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Dermatological and Skeletal Disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Cancer Research","funders":"Memorial Sloan-Kettering Cancer Center","keywords":"Feature (linguistics); Medical imaging; Disease; MEDLINE; Computed tomography","authors":[],"retraction":null,"screen_n_in":null,"score":{"opus":0.006966873779264059,"gpt":0.2581287047792288,"spread":0.2511618309999647,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004246583,0.0002416179,0.0009118298,0.0007082961,0.0001953414,0.0007368329,0.0004937495,0.0004166742,0.001372328],"category_scores_gemma":[0.007354114,0.00007827514,0.0003735486,0.0010123,0.0003421132,0.0008793196,0.0003712715,0.0007113253,0.00053348],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006831663,"about_ca_system_score_gemma":0.00026453,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006387862,"about_ca_topic_score_gemma":0.001650232,"domain_scores_codex":[0.9975993,0.001020171,0.0003673392,0.000273156,0.0005404714,0.0001994667],"domain_scores_gemma":[0.9951028,0.001911886,0.001589353,0.0002605241,0.0008707017,0.0002647136],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.004293069,0.0002059461,0.5278819,0.001243447,0.0004561429,0.003350985,0.0005787552,0.002066988,0.009727767,0.0005587533,0.01070793,0.4389284],"study_design_scores_gemma":[0.0003194002,0.003042968,0.884541,0.0009521884,0.0007729489,0.0274452,0.001316394,0.005573603,0.01542474,0.002296375,0.05825629,0.00005885208],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9206802,0.04833504,0.005828205,0.007451537,0.0002208479,0.0002243214,0.001591889,0.0002496646,0.01541835],"genre_scores_gemma":[0.9888979,0.004496638,0.002506707,0.001641838,0.0003192651,0.00006988234,0.0009867079,0.00004251428,0.001038533],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004246583,"threshold_uncertainty_score":0.02245831,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4417530891","doi":"10.1016/j.esmorc.2025.100116","title":"THE TETRAVALENT DEATH RECEPTOR 5 AGONIST OZEKIBART (INBRX-109) IN CHONDROSARCOMA: RESULTS FROM THE RANDOMIZED, REGISTRATIONAL, PHASE 2 CHONDRAGON STUDY","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Bone Tumor Diagnosis and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Cancer Research","funders":"University of Colorado School of Medicine, Anschutz Medical Campus; European Network for Rare Adult Solid Cancers; Feinberg School of Medicine; Centre Léon Bérard; Universitair Medisch Centrum Groningen; Cleveland Clinic; University College London; Institut Gustave-Roussy; Vanderbilt University; Moffitt Cancer Center; Universiteit Leiden; Leids Universitair Medisch Centrum; University of California, San Francisco; Vanderbilt University Medical Center; Fundació Institut de Recerca Hospital Universitari Vall d’Hebron; Johns Hopkins University; University of Texas MD Anderson Cancer Center; Northwestern University; Vanderbilt-Ingram Cancer Center; Memorial Sloan-Kettering Cancer Center","keywords":"Agonist; Placebo; Clinical trial; Receptor; Phase (matter)","authors":[],"retraction":null,"screen_n_in":null,"score":{"opus":0.02316641315826398,"gpt":0.3242507285497494,"spread":0.3010843153914854,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009564976,0.0007704418,0.001208538,0.0002316813,0.0001894277,0.0006272562,0.000549696,0.0007295541,0.002511831],"category_scores_gemma":[0.0006786146,0.0002375857,0.000879248,0.0002949009,0.0004748099,0.000513589,0.000213239,0.00130878,0.0004655613],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005408481,"about_ca_system_score_gemma":0.0006482577,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001191873,"about_ca_topic_score_gemma":0.003752395,"domain_scores_codex":[0.999657,0.0001802424,0.0000211538,0.00003576924,0.00004559363,0.0000600924],"domain_scores_gemma":[0.9997003,0.0000711126,0.000100066,0.00003201548,0.00002509996,0.00007136873],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8466896,0.00999412,0.002572408,0.001726562,0.002630483,0.00008476347,0.0001181067,0.001316998,0.01591852,0.0004290214,0.003894688,0.1146248],"study_design_scores_gemma":[0.8028005,0.1732344,0.013544,0.0001271305,0.002185375,0.0002148257,0.0001258471,0.001062651,0.002733342,0.0003507065,0.003584719,0.00003665781],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9849835,0.01030892,0.0004569522,0.0004654851,0.0001820182,0.0006570307,0.000787611,0.00008863509,0.00206988],"genre_scores_gemma":[0.988358,0.00610589,0.0006348179,0.0006554947,0.0001370099,0.000550237,0.00142616,0.0000241153,0.002108438],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002511831,"threshold_uncertainty_score":0.008402884,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4417530849","doi":"10.1016/j.esmorc.2025.100092","title":"INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF SPINDLE CELL/ SCLEROSING RHABDOMYOSARCOMA, A PUSH PLATFORM STUDY","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary","funders":"Anschutz Medical Campus, University of Colorado; Università degli Studi di Torino; Albert-Ludwigs-Universität Freiburg; Justus Liebig Universität Gießen; University of Texas MD Anderson Cancer Center; St. Jude Children's Research Hospital; Universitätsklinikum Hamburg-Eppendorf; School of Medicine, Duke University; Ohio State University; University of Pennsylvania; Children's Hospital of Philadelphia; Nationwide Children's Hospital; Massachusetts Institute of Technology","keywords":"Retrospective cohort study; Multicenter study; MEDLINE; Real world data","authors":[],"retraction":null,"screen_n_in":null,"score":{"opus":0.02273181365827817,"gpt":0.3061227501812337,"spread":0.2833909365229555,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008717635,0.0006724041,0.0004900236,0.001007548,0.0006347842,0.0009772386,0.0003890177,0.0003988667,0.002196289],"category_scores_gemma":[0.001208166,0.0005351303,0.0005506554,0.001894463,0.0004137478,0.0007933702,0.0008005549,0.0005134947,0.0005222925],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003739526,"about_ca_system_score_gemma":0.0006528582,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002778848,"about_ca_topic_score_gemma":0.003842747,"domain_scores_codex":[0.9994344,0.0001177585,0.00006643245,0.0001861917,0.00007415614,0.0001210359],"domain_scores_gemma":[0.9991823,0.00009283587,0.0002748483,0.0001453898,0.00009626183,0.0002084781],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001203284,0.0001107173,0.9945489,0.00004177875,0.0002622452,0.0003883917,0.0001805128,0.00005702069,0.0007044149,0.0001090445,0.0003965636,0.001997004],"study_design_scores_gemma":[0.0002082079,0.0005160595,0.9947565,0.00003243835,0.0005699829,0.001165362,0.0008926939,0.0001742458,0.0002274619,0.00008017453,0.001358931,0.00001794726],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.997839,0.0004161702,0.00009865814,0.00002503451,0.000004890292,0.00003206274,0.0006161334,0.000003418855,0.0009646565],"genre_scores_gemma":[0.9980226,0.0002385539,0.0001023305,0.00005614599,0.00002436918,0.0000440408,0.001312135,0.000006526849,0.0001933783],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002778848,"threshold_uncertainty_score":0.007347286,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4417530842","doi":"10.1016/j.esmorc.2025.100077","title":"MANAGEMENT OF THE DUODENUM DURING RESECTION OF PRIMARY RETROPERITONEAL SARCOMA: SURGICAL AND ONCOLOGICAL OUTCOMES FROM A MULTICENTER STUDY","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Duodenum; Multicenter study; Resection; Surgical resection; Segmental resection","authors":[],"retraction":null,"screen_n_in":null,"score":{"opus":0.02062131295544494,"gpt":0.296546458373951,"spread":0.275925145418506,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001331347,0.0002854872,0.0002765771,0.0005192618,0.0003445653,0.0006510091,0.0003578364,0.0003332337,0.0009155174],"category_scores_gemma":[0.002524542,0.0002083014,0.0004988727,0.0007471396,0.000281153,0.0004862883,0.0007045436,0.0003414321,0.0002081945],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003555728,"about_ca_system_score_gemma":0.0003426688,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001484868,"about_ca_topic_score_gemma":0.002010182,"domain_scores_codex":[0.999294,0.0002789887,0.00009373631,0.0001502242,0.0001052598,0.00007762117],"domain_scores_gemma":[0.9973382,0.0003114101,0.00159316,0.0001987952,0.0002080483,0.0003502933],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0002127233,0.00004972295,0.9985299,0.000008799065,0.00006007956,0.0000979633,0.00007796845,0.0000206234,0.0001395418,0.000004369487,0.00003764523,0.0007607103],"study_design_scores_gemma":[0.00003704023,0.0003756516,0.9979304,0.000009858313,0.00006222523,0.0008621879,0.0003378655,0.0001105943,0.0000895722,0.000007840149,0.0001724496,0.00000429908],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9996793,0.0001034401,0.00002932849,0.0000131047,0.000001623241,0.000005913238,0.00008709956,8.705339e-7,0.00007929008],"genre_scores_gemma":[0.9996421,0.00005753077,0.00004379341,0.00001440961,0.000008012606,0.000005718678,0.0002034258,8.940007e-7,0.00002409256],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001484868,"threshold_uncertainty_score":0.007040918,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4417530903","doi":"10.1016/j.esmorc.2025.100079","title":"PREOPERATIVE RADIOTHERAPY AND POSTOPERATIVE COMPLICATIONS AMONG PATIENTS WITH PRIMARY RETROPERITONEAL SARCOMA: A POST HOC ANALYSIS OF THE EORTC-62092 (STRASS) PHASE 3 RANDOMIZED CLINICAL TRIAL","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Randomized controlled trial; Post-hoc analysis; Clinical trial; Radiation therapy; Intention-to-treat analysis; Post hoc","authors":[],"retraction":null,"screen_n_in":null,"score":{"opus":0.01606725772035284,"gpt":0.3322600279144521,"spread":0.3161927701940993,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004025821,0.0007476542,0.001363401,0.000223676,0.0002248471,0.0007334956,0.0004977531,0.0007839238,0.0026385],"category_scores_gemma":[0.003283818,0.0003316898,0.002454717,0.0003184045,0.0004841958,0.0005731898,0.0003792905,0.001219747,0.0002962202],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004224273,"about_ca_system_score_gemma":0.0008303021,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005674752,"about_ca_topic_score_gemma":0.001476484,"domain_scores_codex":[0.9981426,0.001372924,0.000106359,0.0001873494,0.00009037284,0.0001003237],"domain_scores_gemma":[0.9978168,0.0009007127,0.0006988675,0.000183241,0.00008125028,0.0003191454],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9411913,0.002724691,0.03520724,0.0003388995,0.00571869,0.0000518432,0.00004594621,0.0006445029,0.001303473,0.00007051939,0.0006696148,0.0120333],"study_design_scores_gemma":[0.6756104,0.151617,0.1565724,0.0001018801,0.009801525,0.0001580872,0.0000889502,0.003152041,0.0009787424,0.0003839005,0.001484023,0.00005110894],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.996626,0.001751407,0.0001885657,0.0002066002,0.00007576356,0.0002951658,0.0004243291,0.00001585447,0.0004162883],"genre_scores_gemma":[0.9974619,0.0004739045,0.0003038423,0.0002490825,0.0001275227,0.0003605647,0.0005675748,0.000007914949,0.000447679],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004025821,"threshold_uncertainty_score":0.02129084,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4417530897","doi":"10.1016/j.esmorc.2025.100090","title":"CIRCULATING TUMOR DNA IN PATIENTS WITH INTERMEDIATE RISK RHABDOMYOSARCOMA ON ARST1431: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"School of Medicine, Duke University; Università degli Studi di Padova; Centre Léon Bérard; Ohio State University; Institut Gustave-Roussy; Nationwide Children's Hospital","keywords":"Circulating tumor DNA; Rhabdomyosarcoma; Mutation; Retrospective cohort study; Disease; Circulating tumor cell; Cancer","authors":[],"retraction":null,"screen_n_in":null,"score":{"opus":0.003196162349068001,"gpt":0.2168799504972371,"spread":0.2136837881481691,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001930773,0.0004055492,0.0003275746,0.0007868112,0.000461513,0.0005179911,0.0003680908,0.0006383382,0.00166052],"category_scores_gemma":[0.001168899,0.0002675759,0.0002041062,0.0005340114,0.0004433063,0.0002930175,0.000244248,0.0006142696,0.0002331743],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004231064,"about_ca_system_score_gemma":0.0004003633,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005468165,"about_ca_topic_score_gemma":0.003330046,"domain_scores_codex":[0.9997672,0.00002345882,0.00001910973,0.00007020374,0.0000578378,0.00006222554],"domain_scores_gemma":[0.9993259,0.0002334216,0.0001483351,0.0000348455,0.00006590736,0.0001917303],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0003037581,0.0000552662,0.9351748,0.00002769902,0.00003842076,0.04979702,0.0003612897,0.0001816689,0.007007659,0.0001482502,0.001292665,0.005611484],"study_design_scores_gemma":[0.00005746737,0.0003255873,0.8504249,0.00002607165,0.0001280106,0.1411874,0.0007761907,0.0006318744,0.003507976,0.00019966,0.0027001,0.00003479554],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9970836,0.0004685246,0.0002528648,0.000229463,0.00002220974,0.00001316894,0.0004044574,0.00001995125,0.001505686],"genre_scores_gemma":[0.9991288,0.000144201,0.0001388554,0.00009454336,0.00003114782,0.000004627424,0.00023823,0.00000681289,0.0002127094],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005468165,"threshold_uncertainty_score":0.01087266,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4417530898","doi":"10.1016/j.esmorc.2025.100059","title":"DISSECTING TUMOR HETEROGENEITY AND CELL STATE-SPECIFIC THERAPEUTIC TARGETS FROM SINGLE-NUCLEI RNA-SEQ OF CIC::DUX4 ROUND CELL SARCOMA","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Sarcoma; Cell; Tumor cells; Clear-cell sarcoma; Chemotherapy; Cell culture","authors":[],"retraction":null,"screen_n_in":null,"score":{"opus":0.02383050455828387,"gpt":0.2642154732002451,"spread":0.2403849686419612,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003150861,0.0001754516,0.0002833574,0.0002642487,0.0003587578,0.0006142058,0.0001808573,0.0003475508,0.001842359],"category_scores_gemma":[0.0003442918,0.0002189158,0.0001880503,0.0001941469,0.0002556464,0.0002765565,0.0002413529,0.0005433402,0.000568272],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003674906,"about_ca_system_score_gemma":0.000316833,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002148634,"about_ca_topic_score_gemma":0.006838044,"domain_scores_codex":[0.9998376,0.000009770716,0.000006779392,0.00006588976,0.00005402058,0.00002592218],"domain_scores_gemma":[0.999878,0.00004326398,0.00001596197,0.00001096836,0.00003467359,0.00001703431],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0000705592,0.000009570274,0.00175554,0.0000892871,0.00001402158,0.00003632059,0.00009112588,0.0007939531,0.9901571,0.0004588893,0.0005040675,0.006019602],"study_design_scores_gemma":[0.00002487695,0.0001128401,0.04054774,0.00003493732,0.00007595834,0.0002882802,0.0003868487,0.02751055,0.9093071,0.0008224447,0.02085552,0.00003295155],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9183935,0.002413138,0.06279561,0.0003675511,0.0001709936,0.0001064646,0.006901611,0.0007246538,0.008126475],"genre_scores_gemma":[0.9620584,0.00106236,0.02567286,0.0004242259,0.00002815753,0.0001746617,0.004438208,0.0004212823,0.00571976],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002148634,"threshold_uncertainty_score":0.006163299,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4417530862","doi":"10.1016/j.esmorc.2025.100084","title":"PREDICTING FAILURE OF ACTIVE SURVEILLANCE IN DESMOID-TYPE FIBROMATOSIS USING RADIOMICS: AN INTERNATIONAL MULTI-CENTER STUDY","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Soft tissue tumor case studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Mount Sinai Hospital; Princess Margaret Cancer Centre; Sinai Health System","funders":"Sylvester Comprehensive Cancer Center, University of Miami Health Systems; Thomas Jefferson University; University of Miami","keywords":"Radiomics; Fibromatosis; Medical imaging; MEDLINE; Personalized medicine","authors":[],"retraction":null,"screen_n_in":null,"score":{"opus":0.03232056340378441,"gpt":0.3448138099901654,"spread":0.312493246586381,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001350384,0.0003921952,0.0003548047,0.001346345,0.0003815462,0.000882881,0.0004014823,0.0006097026,0.001043403],"category_scores_gemma":[0.003165112,0.0002350721,0.0004917108,0.000863619,0.0004239512,0.0007675593,0.0004734444,0.0005199797,0.0001757013],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002605104,"about_ca_system_score_gemma":0.0002406982,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001779573,"about_ca_topic_score_gemma":0.001911146,"domain_scores_codex":[0.9994814,0.0001943817,0.00006154783,0.0001041743,0.00006813094,0.00009036512],"domain_scores_gemma":[0.9981212,0.0005956976,0.0006313145,0.0001491878,0.0002123987,0.0002902188],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","study_design_scores_codex":[0.0001240374,0.00005256649,0.9981725,0.000005636735,0.00003658732,0.0001720547,0.00008175462,0.0000297518,0.0001638312,0.00001207763,0.00003563919,0.001113405],"study_design_scores_gemma":[0.00001455976,0.0003066295,0.996838,0.00001302492,0.0001194499,0.00133699,0.0005745127,0.0003717362,0.0001197313,0.0000259771,0.0002719596,0.000007419206],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9990903,0.0003071111,0.00007043105,0.00002476929,0.000004211106,0.0000101098,0.00006705386,0.000001485915,0.00042459],"genre_scores_gemma":[0.9996061,0.0001242356,0.00007492002,0.00001523408,0.00001332296,0.000004753048,0.0001165306,0.000001116921,0.00004375584],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001779573,"threshold_uncertainty_score":0.00714159,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4417530895","doi":"10.1016/j.esmorc.2025.100055","title":"IMMUNOSARC2 (COHORT 7A): A SPANISH SARCOMA GROUP (GEIS) PHASE IB TRIAL OF EPIRUBICIN AND IFOSFAMIDE PLUS NIVOLUMAB IN FIRST LINE OF ADVANCED UNDIFFERENTIATED PLEOMORPHIC SARCOMA (UPS)","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Duke Cancer Institute; National Cancer Institute; Knight Cancer Institute, Oregon Health and Science University; University of Texas MD Anderson Cancer Center; University of California, Irvine; USC Norris Comprehensive Cancer Center; McGill University Health Centre; Huntsman Cancer Institute; McGill University; Royal Marsden NHS Foundation Trust; Medical Center, University of Pittsburgh; University of Pittsburgh; Washington University in St. Louis; Moffitt Cancer Center; Centre Hospitalier Universitaire de Bordeaux; University of Southern California; National Institutes of Health; Ohio State University; Memorial Sloan-Kettering Cancer Center; Children's Hospital of Philadelphia","keywords":"Nivolumab; Ifosfamide; Epirubicin; Sarcoma; First line; Chemotherapy","authors":[],"retraction":null,"screen_n_in":null,"score":{"opus":0.02086258826529606,"gpt":0.3186337084991464,"spread":0.2977711202338503,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009758482,0.001025065,0.001056573,0.0003520348,0.0002408458,0.0007434142,0.0004563024,0.0005728833,0.002126771],"category_scores_gemma":[0.0003150186,0.000243126,0.0009053408,0.0002326551,0.0003639967,0.0002924,0.0004112909,0.001109313,0.0005873011],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006656376,"about_ca_system_score_gemma":0.0009404093,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001007576,"about_ca_topic_score_gemma":0.003090456,"domain_scores_codex":[0.9998254,0.00006601544,0.000006900083,0.00003580462,0.00002277174,0.00004307743],"domain_scores_gemma":[0.9998385,0.00001466509,0.00002748787,0.0000206044,0.00001598712,0.00008278759],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5511711,0.03000549,0.04388004,0.001795776,0.004031892,0.0008556432,0.0005069857,0.004394105,0.1108016,0.0007658724,0.01213106,0.2396604],"study_design_scores_gemma":[0.3834125,0.418991,0.1394436,0.000200786,0.002646141,0.002419558,0.0002843755,0.003135151,0.02176462,0.0007150287,0.02691631,0.00007092342],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9929768,0.001977888,0.0003582041,0.0001815946,0.00005760494,0.0008427328,0.001820507,0.00006974029,0.001714727],"genre_scores_gemma":[0.9741068,0.002152167,0.001950439,0.000900907,0.0001435249,0.001644975,0.01514061,0.00004659822,0.003913893],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002126771,"threshold_uncertainty_score":0.007114828,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4417530860","doi":"10.1016/j.esmorc.2025.100076","title":"GENOME-WIDE SEQUENCING ANALYSES REVEAL THE BIOLOGICAL DETERMINANTS OF RESECTION MARGIN STATUS IN PRIMARY RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Mount Sinai Hospital; Princess Margaret Cancer Centre; Hospital for Sick Children; Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"","keywords":"Liposarcoma; Resection margin; Resection; Margin (machine learning); Surgical margin; Radiation therapy","authors":[],"retraction":null,"screen_n_in":null,"score":{"opus":0.05800347749770376,"gpt":0.3336131826764603,"spread":0.2756097051787566,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002836656,0.0001323931,0.0001555329,0.0002991924,0.0001120275,0.0002221501,0.0001189595,0.0001854879,0.001473015],"category_scores_gemma":[0.0004784738,0.0000960131,0.0001523675,0.0002810632,0.0001127291,0.00009135146,0.0001826701,0.0001739787,0.0001685576],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001200057,"about_ca_system_score_gemma":0.00009426591,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003103959,"about_ca_topic_score_gemma":0.0008913883,"domain_scores_codex":[0.9998544,0.00002405312,0.00001442121,0.00004964254,0.00003386551,0.00002356567],"domain_scores_gemma":[0.9997881,0.00007349601,0.00008790375,0.00001153023,0.00001455368,0.00002433559],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.004169595,0.0002225874,0.6872775,0.0001790567,0.0003843256,0.001740741,0.0001798021,0.001395232,0.2661851,0.0001868998,0.0006280399,0.0374511],"study_design_scores_gemma":[0.00009165477,0.000412261,0.9828876,0.00001634559,0.0001448496,0.002240768,0.00009570892,0.001132341,0.01170972,0.0001338205,0.001128869,0.000006056216],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9987341,0.0002189537,0.0002335104,0.00002168863,0.000001328566,0.00000747822,0.0005852367,0.000006969191,0.00019077],"genre_scores_gemma":[0.9989583,0.00005812662,0.0002430059,0.00002009948,0.000001518245,0.000006058014,0.0006007297,0.000002204758,0.0001099405],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001473015,"threshold_uncertainty_score":0.004927695,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4417530877","doi":"10.1016/j.esmorc.2025.100056","title":"INTEGRATED EFFICACY AND SAFETY ANALYSIS OF LETETRESGENE AUTOLEUCEL, A T-CELL RECEPTOR T-CELL THERAPY, ACROSS CLINICAL TRIALS OF PATIENTS WITH SYNOVIAL SARCOMA AND MYXOID/ROUND CELL LIPOSARCOMA","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre","funders":"","keywords":"Clinical trial; Soft tissue sarcoma; Synovial sarcoma; Liposarcoma; Sarcoma; Receptor","authors":[],"retraction":null,"screen_n_in":null,"score":{"opus":0.03792771047108455,"gpt":0.355637362170223,"spread":0.3177096516991384,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002418287,0.0004679381,0.001107991,0.0004540687,0.0001482613,0.0006154129,0.0002574385,0.0003317236,0.0007178481],"category_scores_gemma":[0.0009075025,0.0001944292,0.0007067685,0.0003658963,0.0003390026,0.0004581904,0.0002786761,0.0005493129,0.0001491107],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004880064,"about_ca_system_score_gemma":0.0004043519,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001843497,"about_ca_topic_score_gemma":0.0006646984,"domain_scores_codex":[0.9991881,0.0004043521,0.00007136775,0.0001359981,0.0001239545,0.00007619893],"domain_scores_gemma":[0.9993919,0.0001534977,0.0002176598,0.00006497264,0.00006224722,0.0001096966],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.3694451,0.01159243,0.1881879,0.001406469,0.008963272,0.0002943453,0.0005341557,0.007440384,0.1781155,0.0003605245,0.001418579,0.2322414],"study_design_scores_gemma":[0.03249757,0.4884121,0.4373699,0.00007774402,0.00592224,0.0007660835,0.0003115312,0.004327398,0.02362163,0.0003089786,0.006330317,0.00005451218],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9971603,0.001667603,0.0003629046,0.00003631676,0.0000121799,0.0001497406,0.0002713448,0.00001351245,0.0003260286],"genre_scores_gemma":[0.9980183,0.0004272911,0.0002952794,0.00006362256,0.00001886026,0.0001620937,0.0007307794,0.000005707199,0.0002780268],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002418287,"threshold_uncertainty_score":0.01278931,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W7116631298","doi":"10.1016/j.esmorc.2025.100103","title":"PRELIMINARY DOSE-VOLUME CONSTRAINTS PREDICTING SUBCUTANEOUS TISSUE FIBROSIS FOR LIMB SARCOMA USING THE VORTEX AND IMRIS TRIALS","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Fibrosis; Soft tissue sarcoma; Soft tissue; Thigh; Sarcoma; Subcutaneous tissue; Vortex","authors":[{"name":"Rita Simões","is_ca":false},{"name":"Beatrice Seddon","is_ca":false},{"name":"M. Robinson","is_ca":false},{"name":"Shumona Shelly","is_ca":false},{"name":"Temi Adedoyin","is_ca":false},{"name":"Hakim-Moulay Dehbi","is_ca":false},{"name":"Piers Gaunt","is_ca":false},{"name":"Ana Hughes","is_ca":false},{"name":"Elizabeth Miles","is_ca":false},{"name":"Peter Hoskin","is_ca":false},{"name":"K. Harrington","is_ca":true},{"name":"S. Gulliford","is_ca":false},{"name":"Dr Aisha Miah","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04187978627994771,"gpt":0.3401438212695845,"spread":0.2982640349896368,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002927728,0.0007270177,0.0007778247,0.0003794471,0.0001203402,0.0009364969,0.0006221872,0.0004995393,0.003553933],"category_scores_gemma":[0.006058288,0.0002573043,0.0009508451,0.000289208,0.0003390733,0.0005116835,0.0005020804,0.0009588901,0.0005973894],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004739139,"about_ca_system_score_gemma":0.0006357672,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001620577,"about_ca_topic_score_gemma":0.002847726,"domain_scores_codex":[0.9991885,0.0005652108,0.00002678227,0.00006058239,0.0001213788,0.00003748521],"domain_scores_gemma":[0.9970124,0.002229977,0.00033765,0.0001324959,0.0001256194,0.0001618823],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","study_design_scores_codex":[0.0581124,0.001836739,0.08959938,0.001441854,0.001763749,0.0004459796,0.0002505476,0.6238409,0.05051368,0.005538533,0.01179014,0.1548661],"study_design_scores_gemma":[0.009073995,0.02601736,0.09105819,0.0003846429,0.002290878,0.0009199804,0.0003711991,0.8067424,0.03756566,0.007215303,0.01812305,0.000237379],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9384863,0.007620661,0.03203638,0.001473883,0.0001775048,0.0004611764,0.005177904,0.0005470895,0.0140191],"genre_scores_gemma":[0.9820479,0.0008538825,0.01113968,0.0002736204,0.00006611076,0.0002172003,0.003142782,0.0002757958,0.001983084],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003553933,"threshold_uncertainty_score":0.01548356,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4417530841","doi":"10.1016/j.esmorc.2025.100102","title":"NRG-DT001 PHASE IB TRIAL OF NEOADJUVANT NAVTEMADLIN AND RADIOTHERAPY IN TP53 WILD-TYPE SOFT TISSUE SARCOMA: PRELIMINARY EFFICACY ANALYSIS","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Soft tissue sarcoma; Radiation therapy; Tolerability; Soft tissue; Sarcoma; Clinical trial; Phases of clinical research","authors":[],"retraction":null,"screen_n_in":null,"score":{"opus":0.01758124853013332,"gpt":0.3460718606338129,"spread":0.3284906121036796,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001481269,0.001123046,0.001438768,0.0003654121,0.0002286863,0.0009748028,0.0006890039,0.000711746,0.004347201],"category_scores_gemma":[0.0009054595,0.000354197,0.001224683,0.0004237466,0.0008838779,0.0009253302,0.0002789047,0.002320979,0.0009313656],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001098309,"about_ca_system_score_gemma":0.001679818,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001540607,"about_ca_topic_score_gemma":0.007311065,"domain_scores_codex":[0.9996212,0.0001945857,0.00002365985,0.00005158559,0.00004012218,0.00006881265],"domain_scores_gemma":[0.9994864,0.0001310729,0.00008750326,0.00005185385,0.00002392174,0.0002192104],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6764004,0.02675455,0.005648408,0.001494317,0.002095037,0.0002906414,0.0002638642,0.005833121,0.03707561,0.001266194,0.009482565,0.2333953],"study_design_scores_gemma":[0.4750181,0.4818456,0.01994551,0.0002736801,0.00141055,0.0007718861,0.0002006409,0.003859105,0.005336322,0.0009118477,0.01035469,0.00007191196],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9826583,0.005934659,0.0006413262,0.001023019,0.0003135705,0.001146805,0.00228407,0.0001641054,0.005834176],"genre_scores_gemma":[0.9771409,0.00649865,0.002432858,0.001087048,0.0002168802,0.001471791,0.005292541,0.00005784163,0.005801463],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004347201,"threshold_uncertainty_score":0.01454288,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4417530851","doi":"10.1016/j.esmorc.2025.100096","title":"DATA DRIVEN MODELLING OF SPATIAL HETEROGENEITY IN SOFT TISSUE SARCOMAS IDENTIFIES PROGNOSTIC GROUPS FOLLOWING NEOADJUVANT CHEMOTHERAPY: ANALYSIS OF THE ISG-STS-1001 TRIAL","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Soft tissue; Radiation therapy; Neoadjuvant therapy; Data-driven; Tumour heterogeneity; Sarcoma; Spatial heterogeneity","authors":[],"retraction":null,"screen_n_in":null,"score":{"opus":0.02480526418381184,"gpt":0.2916081398782909,"spread":0.2668028756944791,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01361809,0.001020455,0.002125081,0.0003682182,0.0002041609,0.001223991,0.001649588,0.001231621,0.002572134],"category_scores_gemma":[0.02004842,0.000550767,0.002563993,0.0006108024,0.0006009223,0.0006524508,0.0008521402,0.001748498,0.0004343418],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001036084,"about_ca_system_score_gemma":0.001200381,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005974259,"about_ca_topic_score_gemma":0.004829119,"domain_scores_codex":[0.9966283,0.002775592,0.00008587556,0.0002627847,0.0001024461,0.000144961],"domain_scores_gemma":[0.9780775,0.01856684,0.001318434,0.00119038,0.0003643522,0.0004824322],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","study_design_scores_codex":[0.04494409,0.0009850484,0.06740031,0.0006043208,0.003827788,0.0002758089,0.0001534472,0.8381316,0.001169115,0.003300381,0.009643781,0.02956422],"study_design_scores_gemma":[0.005128821,0.003173667,0.02500819,0.00007254841,0.001477539,0.0001410703,0.00009173618,0.954936,0.0009538068,0.006161253,0.002786652,0.00006855715],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9819874,0.001550414,0.006517288,0.002171864,0.0001009668,0.0001706296,0.006050373,0.0001328104,0.001318069],"genre_scores_gemma":[0.9921141,0.0002103617,0.001975782,0.0002177014,0.00004310473,0.0001806757,0.004267151,0.00003920612,0.0009519299],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01361809,"threshold_uncertainty_score":0.07202017,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4417530885","doi":"10.1016/j.esmorc.2025.100072","title":"OVERCOMING MTOR INHIBITOR RESISTANCE IN PECOMA: UPDATED RESULTS ON AROMATASE INHIBITOR ADDITION FROM A REFERRAL CENTER","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Nitric Oxide and Endothelin Effects","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Cancer Research","funders":"Memorial Sloan-Kettering Cancer Center","keywords":"Discovery and development of mTOR inhibitors; Aromatase inhibitor; Aromatase; Clinical trial; PI3K/AKT/mTOR pathway; Referral","authors":[],"retraction":null,"screen_n_in":null,"score":{"opus":0.01383670230329569,"gpt":0.2705782362036146,"spread":0.2567415339003189,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001497939,0.0003226542,0.0006277562,0.001327687,0.0002103385,0.0008466565,0.0003841644,0.0003453148,0.00190651],"category_scores_gemma":[0.004936446,0.0001744788,0.0006695684,0.00225021,0.0001572948,0.0005694689,0.0004654965,0.0004625205,0.0005812548],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005799872,"about_ca_system_score_gemma":0.0006488084,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003127883,"about_ca_topic_score_gemma":0.003781525,"domain_scores_codex":[0.9980108,0.0004682391,0.0003953048,0.0004066675,0.0005445065,0.0001744013],"domain_scores_gemma":[0.9929783,0.00199007,0.002527104,0.0004438178,0.001662439,0.000398291],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002206428,0.0002779054,0.7952058,0.0006970844,0.0005434907,0.00145443,0.0005495785,0.0006233981,0.004849726,0.00005131355,0.003396152,0.1901449],"study_design_scores_gemma":[0.0001268945,0.001353116,0.9783459,0.000191281,0.0007405115,0.004244072,0.0003119857,0.0003453749,0.002766651,0.00001871948,0.01152465,0.00003081057],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9745482,0.0146552,0.0009852353,0.0004364432,0.00005658127,0.0001044614,0.004569994,0.00007985518,0.004563892],"genre_scores_gemma":[0.9817026,0.008772227,0.001189395,0.0005826585,0.0001952713,0.00005184305,0.006762906,0.00003386376,0.0007092559],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003127883,"threshold_uncertainty_score":0.007921934,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4417530910","doi":"10.1016/j.esmorc.2025.100062","title":"MINNELIDE IS A NOVEL THERAPEUTIC INHIBITOR OF CIC::DUX4 SARCOMA","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Magnesium in Health and Disease","field":"Nursing","cited_by":0,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Sarcoma; Cancer; Immunotherapy; Soft tissue sarcoma; Drug","authors":[],"retraction":null,"screen_n_in":null,"score":{"opus":0.01910175830934603,"gpt":0.3049709616630899,"spread":0.2858692033537439,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000125848,0.0003165151,0.0006106659,0.0002806409,0.0002541816,0.0003943182,0.0004626541,0.0005289561,0.004821803],"category_scores_gemma":[0.0001702372,0.0001068954,0.0003340342,0.0002460507,0.0002027272,0.0003058017,0.0003675626,0.001005528,0.0008200958],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004539744,"about_ca_system_score_gemma":0.0004197869,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007061552,"about_ca_topic_score_gemma":0.001803796,"domain_scores_codex":[0.9999285,0.00001347597,0.000007762177,0.00001267035,0.00001415245,0.0000234462],"domain_scores_gemma":[0.9999623,0.000005770084,0.000008371269,0.000003786756,0.000004478874,0.00001529567],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.01293297,0.001857961,0.00250943,0.002319031,0.000421174,0.001722024,0.0002196873,0.001038736,0.6738777,0.004265992,0.01733465,0.2815008],"study_design_scores_gemma":[0.009222322,0.01857202,0.0183764,0.0003663182,0.0004911965,0.009280284,0.0003721991,0.002311318,0.5795434,0.001735191,0.3596319,0.00009738503],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8456461,0.1075775,0.004374859,0.003779902,0.001180504,0.0005417706,0.001974966,0.000824781,0.03409964],"genre_scores_gemma":[0.958324,0.02532716,0.003476484,0.0008558978,0.0001862156,0.0001720627,0.00154164,0.00005479854,0.01006175],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004821803,"threshold_uncertainty_score":0.01613057,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W7116631937","doi":"10.1016/j.esmorc.2025.100070","title":"EXPLORING ACTIONABLE THERAPEUTIC TARGETS ASSOCIATED WITH SMARCB1 DEFICIENCY IN EPITHELIOID SARCOMA","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Chromatin Remodeling and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Epithelioid sarcoma; Sarcoma; SMARCB1; Disease; Mutation; Soft tissue sarcoma","authors":[{"name":"Ryo Miyamoto","is_ca":true},{"name":"J. Park","is_ca":true},{"name":"David G. Kirsch","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03014984236719089,"gpt":0.2573838991908916,"spread":0.2272340568237007,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004508127,0.0003146863,0.0004570017,0.000357116,0.0001819645,0.0007462089,0.0003681598,0.0004681221,0.002461028],"category_scores_gemma":[0.0002380873,0.0001547136,0.0003032112,0.0002947323,0.0003127136,0.0003789407,0.0003088152,0.0008614332,0.0004880976],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000490547,"about_ca_system_score_gemma":0.0004007564,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002876927,"about_ca_topic_score_gemma":0.0008890514,"domain_scores_codex":[0.9998715,0.00003152199,0.000008590752,0.00001990359,0.00002876094,0.00003970619],"domain_scores_gemma":[0.9999248,0.00002015596,0.00002038674,0.000007327233,0.00001140436,0.00001588895],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.001751628,0.0003895983,0.003376775,0.001264656,0.000128295,0.0009052555,0.0001351609,0.00203999,0.8468226,0.007567442,0.003242918,0.1323757],"study_design_scores_gemma":[0.0009539648,0.006387236,0.01780119,0.0005492888,0.000525424,0.004667094,0.0005935156,0.00599417,0.7634373,0.006702105,0.1923247,0.0000642022],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7033654,0.2555948,0.01444546,0.004681218,0.0004354313,0.0002920805,0.001044514,0.0003313857,0.01980971],"genre_scores_gemma":[0.9398694,0.0514513,0.003410093,0.0006710876,0.00008956218,0.0001509474,0.0006549539,0.00002762396,0.003675025],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002461028,"threshold_uncertainty_score":0.008232892,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4417530843","doi":"10.1016/j.esmorc.2025.100061","title":"JAK/STAT PATHWAY CO-OPERATES WITH CIC-FUSIONS TO DRIVE CIC-REARRANGED SARCOMAS","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Mount Sinai Hospital; University Health Network; Barrie Urology Group","funders":"","keywords":"Sarcoma; Mutation; Cancer; Cell culture","authors":[],"retraction":null,"screen_n_in":null,"score":{"opus":0.01703091906346409,"gpt":0.3220248881436876,"spread":0.3049939690802235,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002487665,0.0002858091,0.0001818452,0.0004953471,0.0003549925,0.0008030718,0.0002588042,0.0006063172,0.006487415],"category_scores_gemma":[0.0003858875,0.0002361901,0.0002992541,0.0003035114,0.0004525112,0.0002682543,0.0005976736,0.001324688,0.002379014],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006313277,"about_ca_system_score_gemma":0.0004271808,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008678036,"about_ca_topic_score_gemma":0.001726208,"domain_scores_codex":[0.9996457,0.00003407219,0.00003060895,0.0000649734,0.0001302638,0.00009440889],"domain_scores_gemma":[0.9997423,0.0000640867,0.00005785534,0.00005123597,0.00001845227,0.00006609764],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.00009551324,0.00006072998,0.001542284,0.00005398861,0.00001807973,0.001073884,0.00005028157,0.0003659861,0.98979,0.001944941,0.001117968,0.0038864],"study_design_scores_gemma":[0.00006603038,0.0001976708,0.01498478,0.00002624224,0.00004081853,0.007868342,0.0001613568,0.005618973,0.9419495,0.0007150575,0.02835297,0.00001817766],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9752308,0.001404563,0.006037291,0.0007730724,0.0002237528,0.0001104971,0.001739654,0.0007422252,0.01373811],"genre_scores_gemma":[0.993222,0.0002628902,0.001154059,0.0001222848,0.00001051808,0.00002473876,0.0006684204,0.0000526832,0.004482463],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006487415,"threshold_uncertainty_score":0.02170259,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}